The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.